Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Lyndsey Runaas"'
Autor:
Guru Subramanian Guru Murthy, Antoine N. Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Mark Litzow, Scott H. Kaufmann, Ehab Atallah
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechan
Externí odkaz:
https://doaj.org/article/950acd891d7543f3b377e2a769eccff7
Autor:
Saurabh Chhabra, Aniko Szabo, Annelie Clurman, Katelynn McShane, Nicholas Waters, Daniel Eastwood, Lisa Samanas, Teng Fei, Gabriel Armijo, Sameen Abedin, Walter Longo, Parameswaran Hari, Mehdi Hamadani, Nirav N. Shah, Lyndsey Runaas, James H. Jerkins, Marcel van den Brink, Jonathan U. Peled, William R. Drobyski
Publikováno v:
Haematologica, Vol 108, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/871d38df3c8a4209b9a71cabe44d7912
Autor:
Kristen Corrao, Siam Rezwan, Ehab Atallah, Laura C Michaelis, Lyndsey Runaas, Alexandra M. Harrington, Sameem Abedin
Publikováno v:
Leukemia Research Reports, Vol 17, Iss , Pp 100329- (2022)
Objective/background: Low risk myelodysplastic syndrome (MDS) is a marrow failure state eventually leading to transfusion dependence. Flow cytometry has previously been demonstrated as prognostic tool in MDS, however not thoroughly studied in lower r
Externí odkaz:
https://doaj.org/article/fe04a5e508e04e589f8f4bfce221f7b7
Autor:
Jordan R. Hanrahan, Leroy J. Seymour, Anna Beckius, Donna Welter, Mandy Kastner, Valarie Ehrlich, Kristine Broge-Reynen, Mary Rodgers, Laura C. Michaelis, Lyndsey Runaas, Ehab L. Atallah, Sameem Abedin, Guru Subramanian Guru Murthy, Ravi Kishore Narra, Mary Fournogerakis, Jessica Schmitz, Andrea Viitala, Elizabeth Larsen, Amber Essenmacher, Gina George, Kim Johnston, Karen Sue Carlson, Nicole Held
Publikováno v:
Blood. 140:5083-5085
Autor:
Muhammad Bilal Abid, Micah Rubin, Nathan Ledeboer, Aniko Szabo, Walter Longo, Meera Mohan, Nirav N. Shah, Timothy S. Fenske, Sameem Abedin, Lyndsey Runaas, Anita D’Souza, Saurabh Chhabra, Binod Dhakal, Mehdi Hamadani
Publikováno v:
Cancer Cell. 40:340-342
Autor:
Sameem Abedin, Skyler Taylor, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C. Michaelis, Karen-Sue Carlson, Ehab L. Atallah
Publikováno v:
Blood. 140:11020-11021
Autor:
Sameem Abedin, Guru Subramanian Guru Murthy, Aniko Szabo, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash G Desai, Mary M Chen, Alexandra M. Harrington, Ehab L. Atallah
Publikováno v:
Blood. 140:157-158
Autor:
Ravi Kishore Narra, Ehab L. Atallah, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Aniko Szabo, Guru Subramanian Guru Murthy
Publikováno v:
Blood. 140:6035-6036
Autor:
Marcelo C. Pasquini, Nirav N. Shah, Bronwen E. Shaw, Mei-Jie Zhang, James H. Jerkins, Timothy S. Fenske, Wael Saber, Mary M. Horowitz, Lyndsey Runaas, Xiaoying Tang, Mehdi Hamadani, Alexis Visotcky, Fenlu Zhu, Robert Thompson, Sameem Abedin, Binod Dhakal, J. Douglas Rizzo, Parameswaran Hari, William R. Drobyski, Saurabh Chhabra, Anita D'Souza
Publikováno v:
Biol Blood Marrow Transplant
Chronic graft-versus-host disease (cGVHD) is major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Ixazomib is an oral, second-generation, proteasome inhibitor that has been shown in preclinical models
Autor:
Mary Beth Graham, Lyndsey Runaas, James H. Jerkins, Michael Frank, Saurabh Chhabra, Sameem Abedin, Aniko Szabo, Nirav N. Shah, Parameswaran Hari, William S. Collier, Muhammad Bilal Abid, Mehdi Hamadani, Marcelo C. Pasquini
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:1670-1678
An increased risk of infections has been described after T cell-replete haploidentical cell transplantation (haploHCT). Cytokine release syndrome (CRS) after haploHCT is a known phenomenon, but the impact of CRS severity on the risk of infections rem